Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Status:
Not yet recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy and safety of induction therapy with MK-3475
and ASG-22CE and radiation therapy with MK-3475 in patients with cT2-4aN0M0 muscle invasive
bladder cancer who are unfit for or refuse radical cystectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Kyoto University Hospital
Collaborators:
Astellas Pharma Inc Kobe City Medical Center General Hospital Merck Sharp & Dohme LLC Osaka Metropolitan University University of Tsukuba